- Home
- ICHR vs OCS Comparison
ICHR vs OCS Comparison
Compare ICHR & OCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ICHR
- OCS
- Stock Information
- Founded
- ICHR 1999
- OCS 2003
- Country
- ICHR United States
- OCS Switzerland
- Employees
- ICHR N/A
- OCS N/A
- Industry
- ICHR Semiconductors
- OCS Biotechnology: Pharmaceutical Preparations
- Sector
- ICHR Technology
- OCS Health Care
- Exchange
- ICHR Nasdaq
- OCS Nasdaq
- Market Cap
- ICHR 1.0B
- OCS 916.3M
- IPO Year
- ICHR 2016
- OCS N/A
- Fundamental
- Price
- ICHR $33.52
- OCS $21.41
- Analyst Decision
- ICHR Strong Buy
- OCS Strong Buy
- Analyst Count
- ICHR 7
- OCS 5
- Target Price
- ICHR $43.00
- OCS $28.80
- AVG Volume (30 Days)
- ICHR 356.4K
- OCS 64.5K
- Earning Date
- ICHR 02-04-2025
- OCS 03-17-2025
- Dividend Yield
- ICHR N/A
- OCS N/A
- EPS Growth
- ICHR N/A
- OCS N/A
- EPS
- ICHR N/A
- OCS N/A
- Revenue
- ICHR $849,040,000.00
- OCS $1,027,571.00
- Revenue This Year
- ICHR $19.19
- OCS $7.98
- Revenue Next Year
- ICHR $11.56
- OCS $853.39
- P/E Ratio
- ICHR N/A
- OCS N/A
- Revenue Growth
- ICHR 4.68
- OCS N/A
- 52 Week Low
- ICHR $25.95
- OCS $10.55
- 52 Week High
- ICHR $45.21
- OCS $23.08
- Technical
- Relative Strength Index (RSI)
- ICHR 56.61
- OCS 52.07
- Support Level
- ICHR $31.33
- OCS $20.95
- Resistance Level
- ICHR $35.56
- OCS $21.86
- Average True Range (ATR)
- ICHR 1.63
- OCS 0.56
- MACD
- ICHR 0.43
- OCS -0.26
- Stochastic Oscillator
- ICHR 78.23
- OCS 56.18
About ICHR Ichor Holdings
Ichor Holdings Ltd is engaged in the design, engineering, and manufacturing of critical fluid delivery subsystems and components for semiconductor capital equipment. The product offerings include gas and chemical delivery subsystems, collectively known as fluid delivery subsystems, which are key elements of the process tools used in the manufacturing of semiconductor devices. The company also manufactures machined components, weldments, and proprietary products for use in fluid delivery systems. Geographically, the company operates in the United States, the United Kingdom, Singapore, Malaysia, Korea, and Mexico, of which a majority of the revenue is generated from Singapore.
About OCS Oculis Holding AG Ordinary shares
Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.